10-Q: Vycor Medical Reports Revenue Growth Amidst Going Concern

Vycor Medical, Inc. reported increased revenue and reduced net loss for Q2 2025, but faces significant liquidity challenges and a 'going concern' warning.

Summary

• Total revenue for the six months ended June 30, 2025, increased by 25% to $932,731, up from $743,246 in the prior year.
• Vycor Medical segment revenue grew by 28% to $900,308, primarily driven by international market expansion.
• NovaVision segment revenue decreased by 13% to $32,423 and continues to incur operating losses.
• Net loss significantly reduced to $14,676 for the six months ended June 30, 2025, compared to $40,646 in the same period last year.
• Operating income increased substantially to $38,340 for the six months ended June 30, 2025, from $6,646 in the prior year.
• The company reported a working capital deficiency of $4,027,184 as of June 30, 2025, an increase from $3,863,561 at December 31, 2024.
• Cash provided by operating activities decreased significantly to $19,724 for the six months ended June 30, 2025, from $87,921 in the prior year.
• The company has an accumulated deficit of $33,428,921 as of June 30, 2025.
• A material weakness in disclosure controls and procedures exists due to the lack of a functioning audit committee with independent members since April 1, 2021.

Sentiment

Score: 3

Explanation: While revenue growth in the Vycor Medical segment and a reduced net loss are positive, the company faces severe liquidity issues, a growing working capital deficiency, and an explicit 'going concern' warning. The reliance on related-party funding, the uncertainty of debt extensions, and the acknowledged material weakness in internal controls due to a non-functioning audit committee indicate significant financial and governance challenges.

Positives

• Overall revenue increased by 25% for the six months ended June 30, 2025, reaching $932,731, up from $743,246 in the prior year.
• Vycor Medical segment revenue grew by 28% to $900,308, primarily driven by international market expansion.
• Net loss significantly reduced to $14,676 for the six months ended June 30, 2025, compared to $40,646 in the same period last year.
• Operating income increased substantially to $38,340 for the six months ended June 30, 2025, from $6,646 in the prior year.
• Research and development expenses increased to $9,963, indicating investment in new product development for the Vycor Medical division.
• Engaged Maxim Group LLC to assist with strategic acquisitions and potential uplisting to a US exchange.

Negatives

• NovaVision segment revenue decreased by 13% to $32,423 for the six months ended June 30, 2025, and continues to incur operating losses of $85,262.
• Gross margin for Vycor Medical decreased from 90% to 83% for the six months ended June 30, 2025, due to validation and shipping costs of new production and sales mix.
• Cash provided by operating activities significantly decreased to $19,724 for the six months ended June 30, 2025, from $87,921 in the prior year.
• Working capital deficiency increased to $4,027,184 as of June 30, 2025, from $3,863,561 at December 31, 2024.
• Accumulated deficit increased to $33,428,921 as of June 30, 2025.
• Total liabilities increased to $4,745,890 as of June 30, 2025.
• Sales commissions decreased by $22,196 due to lower US sales and write-off of historical balances.
• Corporate operating loss increased to $146,618 for the six months ended June 30, 2025, from $79,159 in the prior year.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern due to accumulated losses, negative cash flows from operations, and a significant working capital deficiency of $4,027,184 as of June 30, 2025.
• Uncertainty regarding the extension of a $300,000 term note to EuroAmerican Investment Corp. (plus $544,833 accrued interest) maturing on September 30, 2025.
• Reliance on Fountainhead Capital Management Limited, the largest shareholder, for working capital funding on an as-needed basis, with no guarantee of continued support.
• Potential inability to obtain additional debt or equity funding on acceptable terms or at all, which could lead to delays or curtailment of product development/commercialization or cessation of operations.
• Risk of negative impact on international revenues due to potential retaliatory tariffs from countries like Canada, Japan, the UK, and the EU, despite US manufacturing.
• Material weakness in disclosure controls and procedures due to the lack of a functioning audit committee with independent members since April 1, 2021, leading to ineffective oversight of internal controls.

Future Outlook

The company is executing a plan to achieve revenue growth, focusing on increasing market penetration and international growth for its Vycor Medical division, alongside continued new product development. For NovaVision, the strategy involves partnering with entities for distribution, with management open to licensing, merger, or sale. The company anticipates purchasing approximately $75,000 in new VBAS inventory over the next twelve months and expects limited investing activities. However, it believes it may not have sufficient cash to meet its needs through August 31, 2026, without obtaining additional debt or equity funding.

Management Comments

• The company is continuing to execute on a plan to achieve revenue growth.
• Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.
• The company believes it may not have sufficient cash to meet its various cash needs through August 31, 2026 unless the company is able to obtain additional cash from the issuance of debt or equity securities.
• Fountainhead, the company's largest shareholder, has provided working capital funding to the company on an as-needed basis, although there is no guarantee that this will continue to be the case.
• Management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors, results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Industry Context

Vycor Medical operates in the specialized medical device industry, with its Vycor Medical division focusing on neurosurgical devices and NovaVision on non-invasive vision rehabilitation therapies. The company's strategy to expand internationally for its neurosurgical products aligns with global growth trends in medical technology. Its openness to partnerships, licensing, or sale for NovaVision reflects a common approach for smaller entities in niche digital health or therapy markets to leverage broader distribution networks or consolidate. The engagement of Maxim Group for strategic acquisitions and potential uplisting suggests a move towards greater market presence and access to capital, a common goal for growing medical device companies.

Comparison to Industry Standards

• The filing does not provide specific industry benchmarks or comparable company data for direct assessment.
• The company's persistent net losses, significant accumulated deficit of over $33 million, and increasing working capital deficiency of over $4 million suggest it is not performing at par with established, profitable companies in the broader medical device or healthcare technology sectors.
• The explicit 'going concern' warning and heavy reliance on related-party funding are critical indicators of financial instability, which would typically differentiate it negatively from financially robust industry peers.

Corporate Governance

Legal Proceedings

• No material litigation, claims, or suits as of August 8, 2025.
• An ongoing appeal against a preliminary assessment for Magdeburg City trade tax of €75,000 (approximately $82,000) from June 2012, with an additional interest charge of €12,000 (approximately $13,200) that remains suspended.

Related Party Transactions

• Accrued interest on related party loans totaled $25,142 for the six months ended June 30, 2025.
• Accrued Preferred D Stock dividends totaled $162,185 for the six months ended June 30, 2025, with $113,019 regarding Fountainhead and $41,693 regarding Peter Zachariou.
• Total accrued Preferred D Stock dividends amounted to $2,757,145 as of June 30, 2025.
• Promissory notes to Peter Zachariou total $30,000, due June 25, 2026.
• Promissory notes to Fountainhead Capital Management Limited total $463,373, with due dates between October 2025 and August 2026.
• Fountainhead Capital Management Limited owned 60.9% of the company's Common Stock and 69.7% of its Series D Preferred Stock as of June 30, 2025.
• Peter Zachariou owned 0.15% of the company's Common Stock and 25.7% of its Series D Preferred Stock as of June 30, 2025.
• Adrian Liddell, Chairman, is a consultant to Fountainhead.

Stakeholder Impact

• Shareholders face significant risks due to the company's substantial accumulated deficit, increasing working capital deficiency, and the explicit 'going concern' warning, which could lead to further dilution from potential future equity raises.
• Creditors, particularly those holding the EuroAmerican Investment Corp. note, face elevated risk due to the company's liquidity issues and the uncertainty of debt extensions.
• Employees may face uncertainty regarding job security if the company is unable to secure additional funding, potentially leading to delays, curtailment of operations, or cessation of some activities.
• Customers of Vycor Medical may benefit from continued new product development, while NovaVision customers might experience changes in service delivery depending on the outcome of strategic partnerships or a potential sale.
• Suppliers could face indirect impacts from potential supply chain disruptions due to global trade tariffs, although the company's products are manufactured in the US.

Next Steps

• Continue executing the plan to achieve revenue growth, particularly in the Vycor Medical division.
• Increase market penetration in the US and international growth for Vycor Medical.
• Continue new product development in the Vycor Medical division.
• Explore partnerships, licensing, merger, or sale for the NovaVision segment.
• Seek additional equity or debt funding to meet cash needs through August 31, 2026.
• Address the material weakness in internal controls related to the lack of a functioning audit committee.
• Monitor the maturity of the EuroAmerican Investment Corp. note on September 30, 2025.
• Anticipate purchasing approximately $75,000 in new VBAS inventory over the next twelve months.

Key Dates

Recommendation

Despite revenue growth in the Vycor Medical segment and a reduced net loss, the company faces severe financial distress, evidenced by a substantial and increasing working capital deficiency, negative cash flow from operations, and an explicit 'going concern' warning. The heavy reliance on related-party funding, the uncertainty surrounding a significant debt maturity in September 2025, and a material weakness in corporate governance (lack of independent audit committee) present significant risks. These factors collectively indicate a high probability of further financial challenges, potential dilution, or operational curtailment, making the stock a high-risk investment.

Keywords

Medical Devices, Neurosurgery, Vision Restoration Therapy, SEC Filing, Quarterly Report, Financial Performance, Going Concern, Vycor Medical, NovaVision, VBAS, Healthcare Technology, Medical Equipment